The MUSETTE trial was conducted to determine if a higher dose of OCREVUS IV 600 mg would provide additional benefits to people with relapsing multiple sclerosis. However, the trial did not meet its primary endpoint, showing that the higher dose did not provide additional benefits in slowing disability progression. The results support the currently approved OCREVUS IV 600 mg dose as the optimal dose for treating relapsing multiple sclerosis. The higher dose was well-tolerated with a comparable safety profile to the 600 mg dose and no new safety signals were observed. The data from the trial further support the efficacy and safety profile of the 600 mg dose for relapsing multiple sclerosis. OCREVUS has set a new standard of care in multiple sclerosis and is the most prescribed disease-modifying therapy in the United States, with over 400,000 people treated globally. Roche is developing a novel high concentration formulation for more convenient on-body device delivery to bring OCREVUS treatment closer to home. The company also has a diverse pipeline of formulations and targets in early-stage development for multiple sclerosis. Full data from the MUSETTE trial will be presented at an upcoming medical meeting.